Jump to content

Talk:Array BioPharma

Page contents not supported in other languages.
From Wikipedia, the free encyclopedia

Notability

[edit]

PharmEditor (talk) 00:48, 4 January 2016 (UTC) This company is notable. It is in the NASDAQ biotechnology index. Please remove[reply]

Notability on Wikipedia is defined for companies at WP:CORP - and being listed a NASDAQ index is not in itself a means to demonstrate notability - although it would suggest adequate third-party sources may exist which would then establish notability.
Per WP:CORP: "A company, corporation, organization, school, team, religion, group, product, or service is notable if it has been the subject of significant coverage in secondary sources. Such sources must be reliable, and independent of the subject. A single independent source is almost never sufficient for demonstrating the notability of an organization."
To establish notability, please demonstrate that multiple third-party source discuss the company (ie: not just listing them, nor simply mentioning them in passing, but provide depth of coverage). Note that press-releases reprinted by third-party sources are also not sufficient to demonstrate notability. --- Barek (talkcontribs) - 00:56, 4 January 2016 (UTC)[reply]

Needs independent sourcing

[edit]

The following has almost no independent sourcing and was moved here per WP:PRESERVE. Per WP:BURDEN please do not restore without finding independent, reliable sources, checking the content against them, and citing them, and ensuring that this content has appropriate WP:WEIGHT in the article overall.

Pipeline

As of 2016, Array BioPharma has a number of compounds in clinical development.[1]

Drug Name Stage in Clinical Trials Development Partner Indication Target
Binimetinib (MEK162) Phase 3 None Cancer MEK
Encorafenib (LGX818) Phase 3 Pierre Fabre Cancer[2][3] BRAF
Selumetinib Phase 3 AstraZeneca Cancer MEK
Danoprevir Phase 3 Roche Hepatitis C NS3
Filanesib (ARRY-520) Phase 2 None Multiple myeloma[4] KSP
ARRY-797 Phase 2 None LMNA-related DCM p38
ARRY-502 Phase 2 None Asthma CRTh2
Ipatasertib (GDC-0068) Phase 2 Genentech Cancer AKT
Motolimod (VTX-2337) Phase 2 VentiRX, Celgene Cancer TLR e.g. TLR8[5]
Varlitinib (ASLAN001) Phase 2 ASLAN Cancer Pan-HER
LY2606368 Phase 2 Eli Lilly Cancer CHEK1
LOXO-101 Phase 2 Loxo Oncology Cancer Pan-TRK
ONT-380 Phase 2 Oncothyreon Breast cancer HER2/neu
ARRY-382 Phase 1 None Cancer CSF1R
ARRY-614 Phase 1 None Myelodysplastic syndrome (MDS) p38/Tie2
GDC-0575 Phase 1 Genentech Cancer CHEK1
GDC-0994 Phase 1 Genentech Cancer ERK

References

  1. ^ "Product Pipeline".
  2. ^ "Array, Pierre Fabre global commercialization agreement closes". www.denverpost.com. Denver Post.
  3. ^ "Array BioPharma closes deal with French drug company". 9News. Tegna Corporation.
  4. ^ Gitlin, Jonathan (2011). Multiple Myeloma: New Insights for the Healthcare Professional: 2011 Edition (2011 ed.). National Human Genome Research Institute. Retrieved 4 January 2016.
  5. ^ Immune Stimulant No Help When Added to Chemotherapy for Recurrent Ovarian Cancer. March 2017

-- Jytdog (talk) 19:49, 30 June 2017 (UTC)[reply]